More Than 130 Healthcare Groups Express Support for Legislation Expanding Medicare Patients Access to Pharmacist Services
News provided by
Share this article
Share this article
WASHINGTON, May 25, 2021 /PRNewswire/ Today, more than 130 healthcare groups applauded the introduction of the Pharmacy and Medically Underserved Areas Enhancement Act (S. 1362, H.R. 2759), legislation that will ensure that Medicare beneficiaries in medically underserved areas have access to pharmacists primary care services.
In a letter sent to the bill s original sponsors Sen. Chuck Grassley (R-IA), Sen. Bob Casey (D-PA), Sen. Sherrod Brown (D-OH), Rep. G.K. Butterfield (D-NC), and Rep. David McKinley (R-WV) the healthcare groups, including rural health advocates, consumer groups, and pharmacy organizations, call for the removal of restrictions on seniors access to care.
How Antibiotic Stewardship Programs Play a Vital Role During Public Health Crises pewtrusts.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pewtrusts.org Daily Mail and Mail on Sunday newspapers.
The Pew Charitable Trusts
In March, nearly 40 individuals from across the country will meet with their legislators to urge Congress to take bipartisan action to prioritize the battle against antibiotic resistance: a looming global health threat that threatens the future of modern medicine. As part of The Pew Charitable Trusts’ Stand Up to Superbugs initiative, this year’s ambassadors include health care professionals, public health officials, scientists, farmers and ranchers, veterinarians, superbug survivors, and people who have lost loved ones to an antibiotic-resistant infection. They will meet virtually with federal agency leaders and members of Congress to share their superbug stories and expertise, and urge increased commitment and momentum to preserve the effectiveness of existing antibiotics and develop urgently needed new ones.
Science’s COVID-19 reporting is supported by the Heising-Simons Foundation.
The world’s largest trial of COVID-19 drugs has produced more good news: The anti-inflammatory drug tocilizumab cut the death risk of people hospitalized with the disease, reduced their need for a mechanical ventilator, and shortened time spent in the hospital, investigators of the United Kingdom’s Recovery trial announced today at a press conference. A preprint about the data has been published on medRxiv.
“This is an incredibly significant result,” says Athimalaipet Ramanan, a rheumatologist at the University of Bristol who was not involved in the study but sits on the steering committee of a tocilizumab trial in India. “This is probably only the second drug that has an impact on mortality,” he says, after the steroid dexamethasone. If the data pan out, it’s “fantastic news,” adds Jason Pogue, a pharmacist at the University of Michigan, Ann Arbor, and president of the Society of Infect
Covid 19 coronavirus: With all eyes on Covid-19, drug-resistant infections crept in
28 Jan, 2021 05:00 AM
6 minutes to read
A medical worker disinfects the ICU ward once designated for Covid-19 patients in Wuhan, China. Photo / Getty Images
A medical worker disinfects the ICU ward once designated for Covid-19 patients in Wuhan, China. Photo / Getty Images
New York Times
By: Matt Richtel
The spread of other dangerous germs is surging a result, in part, of the chaotic response to the pandemic. As Covid-19 took hold over the past year, hospitals and nursing homes used and reused scarce protective equipment masks, gloves, gowns. This desperate frugality helped prevent the airborne transfer of the virus.